Veradermics, Incorporated
MANE
$99.69
-$4.14-3.99%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 527.64% | 508.79% | 371.99% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 83.87% | 131.22% | 285.38% | ||
| Operating Income | -83.87% | -131.22% | -285.38% | ||
| Income Before Tax | -50.22% | -119.61% | -285.99% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -50.22% | -119.61% | -285.99% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -50.22% | -119.61% | -285.99% | ||
| EBIT | -83.87% | -131.22% | -285.38% | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | 97.60% | 93.32% | -328.18% | ||
| Normalized Basic EPS | 97.23% | 92.87% | -279.38% | ||
| EPS Diluted | 97.60% | 93.32% | -328.18% | ||
| Normalized Diluted EPS | 97.23% | 92.87% | -279.38% | ||
| Average Basic Shares Outstanding | 5,330.61% | 2,981.03% | 1.75% | ||
| Average Diluted Shares Outstanding | 5,330.61% | 2,981.03% | 1.75% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||